癌/腫瘍プロファイリングの世界市場見通し2016-2022

【英語タイトル】Cancer/Tumor Profiling - Global Market Outlook (2016-2022)

Stratistics MRCが出版した調査資料(SMRC601068)・商品コード:SMRC601068
・発行会社(調査会社):Stratistics MRC
・発行日:2016年9月
・ページ数:147
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥460,650見積依頼/購入/質問フォーム
2-5 UserUSD5,250 ⇒換算¥582,750見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥832,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、癌/腫瘍プロファイリングの世界市場について調査・分析し、癌/腫瘍プロファイリングの世界市場規模、市場動向、関連企業分析などを含め、以下の構成でお届けいたします。
・エグゼクティブサマリー
・序文
・癌/腫瘍プロファイリングの世界市場:市場動向分析
・癌/腫瘍プロファイリングの世界市場:競争要因分析
・癌/腫瘍プロファイリングの世界市場:用途別分析/市場規模
・癌/腫瘍プロファイリングの世界市場:技術別分析/市場規模
・癌/腫瘍プロファイリングの世界市場:地域別分析/市場規模
・癌/腫瘍プロファイリングの北米市場規模
・癌/腫瘍プロファイリングの欧州市場規模
・癌/腫瘍プロファイリングのアジア市場規模
・癌/腫瘍プロファイリングの世界市場:主な市場開拓
・関連企業分析
【レポートの概要】

According to Stratistics MRC, the Global Cancer/Tumor Profiling market is expected to grow from $23.04 billion in 2015 to reach $78.69 billion by 2022 with a CAGR of 19.2%. Increasing cases of cancer and the need for therapy are the major factors influencing the market growth. Moreover, high investments in R&D, technological developments, and demand for safer medicines are the factors fostering the market growth. However, low awareness among clinicians about options and potential of cancer profiling are the major challenges for this market.

By application, personalized medicines segment leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth is attributed by unique characteristics of this segment in examining and prognosis of cancer disease. North America commands the market due to the presence of leading cancer profiling industry leaders. Asia Pacific is expected to witness huge growth due to raising incidence of cancer in this region.

Some of the key players in global Cancer/Tumor profiling market include Agendia Nv, Biotheranostics, Boreal Genomics, Inc., Caris Life Sciences, Genomic Health, Inc., Illumina, Inc., Life Technologies Corporation, Nanostring Technologies, Neogenomics Laboratories, Oncopath Laboratory, Oxford Gene Technology Ltd, Precision Therapeutics, Inc., Proteome Sciences Plc, Rational Therapeutics, and Ribomed Biotechnologies.

Applications Covered:
• Biomarker Discovery
• Diagnostics
• Personalized Medicine
• Prognosis
• Research Applications

Technologies Covered:
• Fluorescence/Chromogenic In Situ Hybridization
• Immunohistochemistry
• Microarray
• Next-Generation Sequencing
• Quantitative PCR

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Technology Analysis
3.8 Emerging Markets

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cancer/Tumor Profiling Market, By Application
5.1 Introduction
5.2 Biomarker Discovery
5.3 Diagnostics
5.4 Personalized Medicine
5.5 Prognosis
5.6 Research Applications

6 Global Cancer/Tumor Profiling Market, By Technology
6.1 Introduction
6.2 Fluorescence/Chromogenic In Situ Hybridization
6.3 Immunohistochemistry
6.4 Microarray
6.5 Next-Generation Sequencing
6.6 Quantitative PCR

7 Global Cancer/Tumor Profiling Market, By Geography
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.2.6 Rest of Europe
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 Rest of the World
7.4.1 Middle East
7.4.2 Brazil
7.4.3 Argentina
7.4.4 South Africa
7.4.5 Egypt

8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 Company Profiling
9.1 Agendia Nv
9.2 Biotheranostics
9.3 Boreal Genomics, Inc.
9.4 Caris Life Sciences
9.5 Genomic Health, Inc.
9.6 Illumina, Inc.
9.7 Life Technologies Corporation
9.8 Nanostring Technologies
9.9 Neogenomics Laboratories
9.10 Oncopath Laboratory
9.11 Oxford Gene Technology Ltd
9.12 Precision Therapeutics, Inc.
9.13 Proteome Sciences Plc
9.14 Rational Therapeutics
9.15 Ribomed Biotechnologies

List of Tables
Table 1 Global Cancer/Tumor Profiling Market, By Region (2013-2022) ($MN)
Table 2 Global Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 3 Global Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 4 Global Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 5 Global Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 6 Global Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 7 Global Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 8 Global Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 9 Global Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 10 Global Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 11 Global Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 12 Global Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 13 Global Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
Table 14 North America Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
Table 15 North America Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 16 North America Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 17 North America Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 18 North America Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 19 North America Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 20 North America Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 21 North America Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 22 North America Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 23 North America Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 24 North America Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 25 North America Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 26 North America Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
Table 27 Europe Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
Table 28 Europe Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 29 Europe Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 30 Europe Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 31 Europe Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 32 Europe Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 33 Europe Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 34 Europe Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 35 Europe Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 36 Europe Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 37 Europe Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 38 Europe Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 39 Europe Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
Table 40 Asia Pacific Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
Table 41 Asia Pacific Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 42 Asia Pacific Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 43 Asia Pacific Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 44 Asia Pacific Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 45 Asia Pacific Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 46 Asia Pacific Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 47 Asia Pacific Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 48 Asia Pacific Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 49 Asia Pacific Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 50 Asia Pacific Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 51 Asia Pacific Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 52 Asia Pacific Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
Table 53 RoW Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
Table 54 RoW Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 55 RoW Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 56 RoW Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 57 RoW Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 58 RoW Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 59 RoW Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 60 RoW Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 61 RoW Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 62 RoW Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 63 RoW Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 64 RoW Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 65 RoW Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)



【レポートのキーワード】

癌プロファイリング、腫瘍プロファイリング、バイオマーカー開発、診断、医療、医薬品、免疫組織化学、マイクロアレイ

★調査レポート[癌/腫瘍プロファイリングの世界市場見通し2016-2022] (コード:SMRC601068)販売に関する免責事項を必ずご確認ください。
★調査レポート[癌/腫瘍プロファイリングの世界市場見通し2016-2022]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆